Director sold ~$345K of Corcept Therapeutics
Scheduled in advanceLoading…
Traded Jun 2, 2026 · Filed Jun 5, 2026
Corcept Therapeutics's Chief Development Officer sold $1.41M of Corcept Therapeutics shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,412,000
Shares × reported transaction price
33 days after results of Apr 30, 2026, 57 days before results of Jul 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +14.2% | +0.6% | +13.6% |
| 30 days | +26.1% | +1.9% | +24.3% |
| 90 days | +55.3% | +4.8% | +50.5% |
Past results only. Not a forecast.
Director sold ~$345K of Corcept Therapeutics
Scheduled in advanceDirector sold ~$487K of Corcept Therapeutics
Scheduled in advanceA board member of Corcept Therapeutics sold $1.69M of Corcept Therapeutics shares. Nobody planned it ahead of time.